论文部分内容阅读
目的探讨超声检查对结核性胸膜炎患者胸腔注射尿激酶疗效评估的价值。方法收集2009年1—6月113例结核性胸膜炎的病例资料,对比分析20例胸腔注射尿激酶治疗前后超声检查结果。结果胸腔积液超声改变分为3型,Ⅰ型49例(43.4%),Ⅱ型51例(45.1%),Ⅲ型13例(11.5%)。治疗后,未注射尿激酶组:Ⅰ型胸膜增厚率为12.2%,Ⅱ型为69.4%,Ⅲ型为100%,3组间差异有统计学意义。注射尿激酶组:Ⅱ型胸膜增厚的发生率33.3%,与未注药组(69.4%)比较,差异有统计学意义,Ⅲ型为100%,与未注药组比较差异无统计学意义。结论超声检查对于胸腔注入尿激酶的疗效评估有一定参考价值。
Objective To investigate the value of ultrasonography in assessing the efficacy of thoracic injection of urokinase in patients with tuberculous pleurisy. Methods The data of 113 cases of tuberculous pleurisy from January to June in 2009 were collected and the results of ultrasound examination before and after treatment of 20 cases of thoracic cavity were compared. Results Ultrasound of pleural effusion was divided into three types: 49 cases (43.4%) of type Ⅰ, 51 cases (45.1%) of type Ⅱ and 13 cases (11.5%) of type Ⅲ. After treatment, urokinase group was not injected: type Ⅰ pleural thickening rate was 12.2%, type Ⅱ was 69.4%, type Ⅲ was 100%, the difference between the three groups was statistically significant. The incidence of type Ⅱ pleural thickening in injected urokinase group was 33.3%, which was significantly different from that in non-injected group (69.4%), the type Ⅲ was 100%. There was no significant difference between the two groups . Conclusion Ultrasound examination for the evaluation of the efficacy of pleural injection of urokinase have a certain reference value.